| Foreword |
xi |
| Preface |
xiii |
| Chapter 1. Introduction |
1 |
| What Is Multiple Myeloma? |
1 |
| Historical Accounts |
1 |
| Nursing Contributions to Myeloma Care |
3 |
| Collaboration and Partnership |
3 |
| Forging Ahead |
4 |
| References |
4 |
| Chapter 2. Anatomy and Physiology |
9 |
| The Immune System |
9 |
| Innate and Acquired Immunity |
9 |
| Adaptive Immunity: Humoral and Cellular |
10 |
| Organs of the Immune System |
11 |
| Cells Responsible for Innate Immunity |
11 |
| Cells Responsible for Adaptive Immunity |
12 |
| Immunoglobulins |
18 |
| Cytokines |
21 |
| Conclusion |
24 |
| References |
25 |
| Chapter 3. Pathophysiology |
27 |
| Introduction |
27 |
| The Role of Genetics |
27 |
| Cytokines |
34 |
| Conclusion |
38 |
| References |
38 |
| Chapter 4. Epidemiology |
41 |
| Introduction |
41 |
| Etiology |
41 |
| Incidence |
42 |
| Risk Factors |
42 |
| Conclusion |
49 |
| References |
49 |
| Chapter 5. Patient Assessment |
55 |
| Introduction |
55 |
| Clinical Manifestations of Multiple Myeloma |
55 |
| Diagnosis of Myeloma |
61 |
| Staging |
63 |
| Diagnostic Tests and Procedures |
64 |
| Prognostication |
68 |
| Conclusion |
72 |
| References |
72 |
| Chapter 6. Treatment of Newly Diagnosed, Transplant-Ineligible Patients |
77 |
| Introduction |
77 |
| A New Era |
77 |
| Standard Autologous Stem Cell Transplant |
78 |
| A Philosophical Divide |
79 |
| Reduced-Intensity Autologous Stem Cell Transplant |
80 |
| Conventional Therapies |
81 |
| Maintenance Therapy |
100 |
| Conclusion |
103 |
| References |
104 |
| Chapter 7. Treatment of Newly Diagnosed, Transplant-Eligible Patients |
109 |
| Introduction |
109 |
| Single or Tandem Autologous Stem Cell Transplantation |
110 |
| Allogeneic Stem Cell Transplantation |
116 |
| Nonmyeloablative or Reduced-Intensity Allogeneic Stem Cell Transplantation |
117 |
| Maintenance Therapy Following Stem Cell Transplantation |
119 |
| Conclusion |
120 |
| References |
121 |
| Chapter 8. Treatment of Relapsed or Refractory Multiple Myeloma |
125 |
| Introduction |
125 |
| Symptomatic and Asymptomatic Relapse |
130 |
| Imaging in Patients With Relapsed Multiple Myeloma |
131 |
| Use of Radiation Therapy in Relapsed Multiple Myeloma |
134 |
| The Role of Bisphosphonates |
135 |
| Treatment Modalities for Relapsed Multiple Myeloma |
137 |
| Conclusion |
148 |
| References |
148 |
| Chapter 9. Management and Evaluation of Patients Receiving High-Dose Chemotherapy With Stem Cell Transplantation |
155 |
| Introduction |
155 |
| Patient Evaluation |
156 |
| Human Leukocyte Antigen Typing |
159 |
| Stem Cell Mobilization |
159 |
| Stem Cell Collection |
161 |
| Stem Cell Processing and Cryopreservation |
162 |
| Stem Cell Transplantation |
163 |
| Engraftment or Recovery Phase |
165 |
| Conclusion |
166 |
| References |
170 |
| Chapter 10. Management and Evaluation of Patients Receiving Novel Agents |
173 |
| Introduction |
173 |
| Thalidomide |
173 |
| Lenalidomide |
178 |
| Bortezomib |
180 |
| Pegylated Liposomal Doxorubicin |
183 |
| Future Novel Agents |
187 |
| Conclusion |
187 |
| References |
187 |
| Chapter 11. Patient Teaching |
195 |
| Introduction |
195 |
| How to Teach |
196 |
| What to Teach |
204 |
| Conclusion |
225 |
| References |
225 |
| Chapter 12. Survivorship Issues |
231 |
| Introduction |
231 |
| Continuum of Care |
232 |
| Bone Health and Mobility |
233 |
| Renal Function |
237 |
| Health Maintenance |
241 |
| Psychosocial Issues |
242 |
| Conclusion |
254 |
| References |
254 |
| Chapter 13. Nursing Research |
257 |
| Introduction |
257 |
| Nursing Research Topics in Multiple Myeloma |
258 |
| Gaps in the Literature |
264 |
| Future Scenario of Nursing Research in Myeloma |
265 |
| Conclusion |
265 |
| References |
265 |
| Chapter 14. On the Horizon: Future Considerations |
267 |
| Introduction |
267 |
| Ongoing Research Studies |
267 |
| Promising Clinical Trials |
268 |
| Cellular and Molecular Genetics |
270 |
| Advances in Imaging |
271 |
| Conclusion |
272 |
| References |
272 |
| Index |
279 |